Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDP in Aggressive Non-Hodgkin's Lymphoma
NCT00491127Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in non-Hodgkin lymphoma (NHL), sponsored by Eli Lilly and Company. Primary endpoint: Response Rate. Started Apr 2003; status: completed.
02
Drugs
gemcitabine
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00491127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491127.